Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replacement,Treatment of dehydration,Maintenance of hydration and caloric supply in patients unable to take oral fluids,Diluent for compatible medications
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: not applicable as it is rapidly metabolized; the half-life of infused glucose is approximately 1.5-2 hours in healthy individuals, but prolonged in conditions like diabetes. Sodium: biological half-life is 10-20 hours, depending on fluid balance and renal function.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose undergoes glycolysis and subsequent oxidation via the citric acid cycle. Sodium chloride is not metabolized; it is excreted unchanged by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of intact dextrose under normal conditions. Sodium and chloride are primarily excreted renally; sodium excretion is regulated by glomerular filtration and tubular reabsorption, while chloride follows sodium. In patients with normal renal function, >90% of infused sodium and chloride are excreted in urine within 24-48 hours.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible binding to plasma proteins. Sodium: minimal binding (approx. 0-10%) to albumin and other proteins. Chloride: not significantly protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: distributes into total body water, approximately 0.55-0.65 L/kg (based on 60% of body weight as water in adults). Sodium: distributes into extracellular fluid, approximately 0.20-0.25 L/kg. Chloride: similar to sodium, extracellular fluid, approximately 0.20 L/kg.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% for all components.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
For GFR < 10 m L/min: reduce to 50% of standard dose or avoid due to risk of volume overload and hypernatremia; monitor closely for signs of fluid overload and electrolyte disturbances.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Not required: no dose adjustment needed for hepatic impairment.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous; dose based on daily maintenance fluid requirements: 0-10 kg: 100 m L/kg/day; 10-20 kg: 1000 m L + 50 m L/kg for each kg over 10; >20 kg: 1500 m L + 20 m L/kg for each kg over 20. Infusion rate adjusted to patient's clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution: lower initial doses and slower infusion rates recommended to avoid fluid overload; monitor renal function and electrolyte balance.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Use with caution in patients with congestive heart failure, renal impairment, or hyperglycemia,Monitor serum glucose, electrolytes, and fluid status,Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or stress-induced insulin resistance,Not for use in patients with intracranial or intraspinal hemorrhage or in patients who are comatose with hyperglycemia
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperglycemia,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia),Patients with known allergies to corn or corn products (dextrose derived from corn)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid excessive intake of high-sodium foods such as processed snacks, canned soups, and fast foods to prevent exacerbation of sodium overload. No specific food interactions with dextrose; however, diabetic patients should monitor carbohydrate intake and adjust insulin accordingly. Alcohol may impair glucose metabolism and enhance hypoglycemia risk; avoid or limit consumption.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe when indicated for maternal hydration or electrolyte balance; avoid excessive dextrose causing maternal hyperglycemia which can lead to fetal hyperinsulinism and neonatal hypoglycemia.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Excreted into breast milk in small amounts; M/P ratio not clinically relevant. Dextrose and sodium chloride are normal milk components. Considered compatible with breastfeeding; monitor infant for signs of electrolyte imbalance if high doses administered to mother.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustment required for dextrose 5% and sodium chloride 0.45% in pregnancy. However, pregnant women have increased plasma volume; consider monitoring for fluid overload in conditions like preeclampsia. Insulin resistance may require glucose monitoring if large volumes are infused.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This isotonic solution (D5 0.45% Na Cl) provides 170 kcal/L as dextrose and 77 m Eq/L sodium, 77 m Eq/L chloride. Use cautiously in patients with hyponatremia or sodium retention (heart failure, cirrhosis, renal impairment). Monitor serum glucose in diabetic patients; may cause hyperglycemia. Not suitable for resuscitation due to low sodium content. Avoid in patients with known allergy to corn-derived dextrose.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any shortness of breath, swelling in legs, or rapid weight gain, as these may indicate fluid overload.,Inform your healthcare provider if you have diabetes, as this solution contains sugar and may affect blood glucose levels.,Tell your doctor if you have a history of kidney problems, heart failure, or high blood pressure.,Do not consume extra salt or salty foods without consulting your doctor.,Notify your nurse immediately if you experience pain, redness, or swelling at the infusion site.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is a Electrolyte that works by Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is: Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe whe. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.